AARTIPHARM Aarti Pharmalabs Q1 FY26 results (Apr–Jun 2025) and concall
Aarti Pharmalabs reported a mixed Q1 FY26, with standalone EBITDA and PAT showing healthy growth of 14% and 9% respectively, despite a slight dip in standalone revenue. Consolidated figures were impacted by an accounting change for the Ganesh Polychem joint venture, making direct comparisons difficult. The company is progressing well on its Xanthine capacity expansion and the new Atali greenfield project, with commercial production expected soon. Management remains confident in achieving its full-year guidance for CDMO and API growth, driven by strategic focus on regulated markets and new capa
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 458 | 538 | 564 | 386 |
| EBITDA | 94 | 129 | 146 | 93 |
| Net profit | 55 | 74 | 88 | 50 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
